AZN:LSEAstraZeneca PLC Analysis

AstraZeneca is delivering solid top‑line growth with double‑digit expansion in oncology and rare disease, while maintaining strong operating margins and robust free cash flow that comfortably cover its dividend. The company’s low beta and increasing volume suggest a defensive profile with growing investor interest, and the current dividend yield of around 1.7% appears sustainable given a payout ratio below 50% and ample cash generation.
Technically, the stock trades just above its 20‑day simple moving average, the RSI sits in the mid‑40s indicating no extreme overbought or oversold pressure, and the MACD histogram has turned positive, signaling a modest bullish bias despite a neutral overall trend. However, the discounted cash‑flow model places fair value well below the market price, implying limited upside in the near term unless the pipeline—particularly the emerging RNA‑targeted small‑molecule platform—accelerates revenue growth.